This week's roundup of Houston innovators includes Navin Varadarajan of the University of Houston, Kelly Pracht of nVenue, and Atul Varadhachary of Fannin. Photos courtesy

Editor's note: Every week, I introduce you to a handful of Houston innovators to know recently making headlines with news of innovative technology, investment activity, and more. This week's batch includes two health tech innovators and a sportstech CEO.

Kelly Pracht, CEO and co-founder of nVenue

Kelly Pracht joins the Houston Innovators Podcast to discuss how she's expanded nVenue to new sports. Photo courtesy of nVenue

All though career technologist Kelly Pracht began her entrepreneurial journey with her favorite sport, baseball, she's recently expanded the data-backed, fan-engaging sports betting platform to new sports.

Pract, who spent nearly 20 years designing technologies at Hewlett Packard Enterprise, founded nVenue in 2019 after realizing that, while there's endless data and stats available in baseball, there's nothing that exists for fans to engage in that data in real time. So, she set out to build it herself.

At first, the platform launched as a direct-to-fans platform, but Pracht says on the Houston Innovators Podcast that the company pivoted to B-to-B amid its participation in the Comcast SportsTech accelerator.

"The industry was super hungry for fan engagement and sports betting, and we were one of the only companies that could do it," she says on the show. "We found this huge product-market fit of the whole industry wanting ways to engage and bet in real time." Read more.

Exclusive: 2 Houston health care institutions team up to develop cancer-fighting treatments

Fannin Partners and the University of Texas MD Anderson Cancer Center have teamed up to develop drugs based on Raptamer, the creation of Fannin company Radiomer Therapeutics. Photo via Getty Images

Two Houston organizations announced a new collaboration in a major move for Houston’s biotech scene.

Fannin Partners and the University of Texas MD Anderson Cancer Center have teamed up to develop drugs based on Raptamer, the creation of Fannin company Radiomer Therapeutics.

“Raptamers combine antibody level affinities with desirable physical and pharmacokinetic properties, and a rapid path to clinic,” Dr. Atul Varadhachary, CEO of Radiomer Therapeutics and Fannin managing partner, Varadhachary, explained to InnovationMap in May. “We are deploying this unique platform to develop novel therapies against attractive first-in-class oncology targets.” Read more.

Earlier this year, Varadhachary joined the Houston Innovators Podcast to discuss Fannin's innovation approach and contribution to medical development in Houston. Listen to the episode below.

Navin Varadarajan, M.D. Anderson Professor of William A. Brookshire Chemical and Biomolecular Engineering at University of Houston

The University of Houston's Navin Varadarajan explains that while COVID vaccines prevent advanced disease, they don’t prevent transmission. But he has a solution. Photo via UH

Since the force of COVID-19 hit globally in 2020, scientists have made efficient progress in the fight against it. As Dr. Navin Varadarajan puts it, vaccines have “allowed us to become a society again.”

And he should know, the M.D. Anderson Professor of William A. Brookshire Chemical and Biomolecular Engineering at University of Houston just published back-to-back studies for nasal sprays that combat viruses. One, the NanoSTING therapeutic, has proven effective in treating strains of SARS-CoV-2 and the flu virus. The other, NanoSTING-NS Pan-coronavirus Vaccine is targeted at preventing the transmission of multiple COVID variants altogether.

Why a nasal vaccine? Varadarajan explains that while COVID vaccines prevent advanced disease, they don’t prevent transmission.

“Intramuscular vaccines do not facilitate a component of peer immunity called mucosal immunity, which takes care of these points of entries, these wet surfaces, which can be of the nose and the wet surfaces of the nose, and so they don't prevent transmission,” he tells InnovationMap. “So I can be vaccinated, I pick up a small infection that's confined largely to my nostrils, and I can still pass it on to vulnerable people, the aged, the immunocompromised people who have all the drugs they're taking to fight other things, like cancer patients. And so for them, the vaccines tend to be less efficacious, and if I transfer it to them, unfortunately they can end up in a hospital, right? And so preventing transmission is the way to end this cycle.” Read more.

Kelly Pracht joins the Houston Innovators Podcast to discuss how she's expanded nVenue to new sports. Photo courtesy of nVenue

All bets are on: Houston innovator expands sports betting platform for enhanced fan engagement

HOUSTON INNOVATORS PODCAST EPISODE 250

All though career technologist Kelly Pracht began her entrepreneurial journey with her favorite sport, baseball, she's recently expanded the data-backed, fan-engaging sports betting platform to new sports.

Pract, who spent nearly 20 years designing technologies at Hewlett Packard Enterprise, founded nVenue in 2019 after realizing that, while there's endless data and stats available in baseball, there's nothing that exists for fans to engage in that data in real time. So, she set out to build it herself.

At first, the platform launched as a direct-to-fans platform, but Pracht says on the Houston Innovators Podcast that the company pivoted to B-to-B amid its participation in the Comcast SportsTech accelerator.

"The industry was super hungry for fan engagement and sports betting, and we were one of the only companies that could do it," she says on the show. "We found this huge product-market fit of the whole industry wanting ways to engage and bet in real time."

nVenue's growth over the years, which included a partnership with Apple TV for onscreen analytics during Friday night baseball broadcasts and a $3.5 million seed funding raise last year, has been steady, and now the platform has expanded into new sports.

"Our vision was never just baseball," Pracht, who developed her technology by attending games at Minute Maid Park, says. "What a wonderful run the Astros have had since back in 2015. It was the perfect place to develop, but our vision was always that this technology — in order to do what I wanted it to do — needed to be open to all sports. As sports fans, we watch a lot of sports."

Through partnerships with the NBA and NASCAR, nVenue has officially expanded to basketball and motor sports — two sports with their own data volume and challenges. Pracht says it's important to her, with each new sport nVenue enters into, that she takes the time to learn and engage with each sport — something partnering with the professional leagues has helped with. Ultimately, Pracht explains, she's engaging with fans just like her platform does.

"The process is the same, and that's my unique speciality in life — taking something that's very complicated and breaking it down into a way that's more simple and usable," she says. "When it comes to predicting live sports — whether it's NASCAR, golf, or cricket — it comes down to watching the fan and understand what their doing."

This week's roundup of Houston innovators includes Kelly Pracht of nVenue, Aimee Gardner of SurgWise, and Kelly Avant of Mercury. Courtesy photos

3 Houston innovators to know this week

who's who

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from sports tech to venture capital — recently making headlines in Houston innovation.

Kelly Pracht, CEO and co-founder of nVenue

nVenue's proprietary predictive analytics appear at the bottom right corner of the screen on Apple TV broadcasts. Photo via nvenue.com

Next time you're watching an Astros game on Apple TV, check the bottom right-hand side of the screen. That prediction data comes by way of a Texas startup with deep Houston roots. nVenue, co-founded by Houstonian Kelly Pracht, struck a deal earlier this year that allowed her data-driven sports analytics platform on the screens of baseball viewers this season.

"In under two weeks we structured the deal, convinced them it worked, pulled together every bit of testing we could — by then we only had one week of pre-season games to test — and we pulled it off," Pracht says.

The technology has a lot of potential when it comes to microbetting — a part of sports fandom that's growing by the second. Click here to read more.

Aimee Gardner, CEO and president of SurgWise

SurgeWise is giving surgical teams the right support for hiring. Photo via SurgWise.com

Hiring surgeons is a whole thing — tons of paperwork, inequitable and archaic processes, and lots of medical practitioners' time wasted. Five years ago, Aimee Gardner came up with a solution and founded SurgWise Consulting, where she serves as president and CEO.

"We help provide assessments to help screen competencies and attributes that people care about," Gardner says. "(Those) are really hard to assess, but really differentiate people who really thrive in training in their careers and people who don't."

Now, Gardner is tapping into the last five years of data she's accumulated and has big plans for developing a tech platform for her solution. Click here to read more.

Kelly Avant, investment associate at Mercury Fund

Kelly Avant, investment associate at Houston-based Mercury Fund, shares how and why she made her way into the venture capital arena. Photo courtesy of Mercury

Kelly Avant's resume might not make sense to you at first. She went from a gender studies major in undergrad, followed by a stint in the Peace Corps, before heading to law school. After moving on to get her MBA over her JD, Avant realized a way she could really make the biggest impact: venture capital.

"VC is an awesome way to shape the future in a more positive way because you literally get to wire money to the most innovative thinkers, who are building solutions to the world’s problems," Avant tells InnovationMap.

Avant joined the Mercury Fund team last year as an MBA associate before joining full time as investment associate. Now, after completing her MBA from Rice University this month, Avant tells InnovationMap why she's excited about this new career in investment in a Q&A. Click here to read more.


nVenue's proprietary predictive analytics appear at the bottom right corner of the screen on Apple TV broadcasts. Photo via nvenue.com

This Houston-born sports tech is changing the game when it comes to fan-accessible data

by the numbers

Using technology to solve big problems has always been Kelly Pracht's career, but she never thought she'd be able use her skills for the sports world she's a lifelong fan of.

After spending nearly 20 years at HP Inc. in various leadership roles and across technology, Pract was watching a baseball game when something clicked for her. Baseball — and its endless data points and metrics — wasn't serving up analytics that the fans cared about. Teams and leagues had their own metic priorities, but fans just want to engage with the game, their team, and the players.

"I saw a gap in how we handle the data coming from the field and how that can impact the fan — and nobody was getting it right," Pracht, co-founder and CEO of nVenue, tells InnovationMap. "I saw technologists coming up with the most nonsensical solutions. For fans like me, coming from my crazy sports family from West Texas where my dad was a coach, I knew that these solutions were a huge miss."

She gives the example of a wearable technology for the viewer at home that can feel what it feels like for the players on the field who get hit. Pracht says it seems like companies were trying to fit technology into the sport, rather than thinking of what the fans really wanted.

She had the idea for a data-driven fan tool in 2017 and nVenue was born. She started building out the code and the team started testing it out at Astros games at Minute Maid.

"What great years to develop this platform. It was fun — these were not boring baseball games," Pracht says. The Astros have won their division four out of the past five years, including winning the World Series in 2017.

Kelly Pracht is the CEO and co-founder of nVenue. Photo courtesy of nVenue

At first, nVenue was using historical data, and that in itself was impressive. But then, Pracht and her team decided to take it live. After building its proprietary analytics platform, nVenue could use data to make predictions in real time.

"We spent over a year — all of 2019 — mastering timing and putting it into a platform," Pracht says, explaining how they built out the artificial intelligence and designed an app for fans to interface with. "We wanted to be able to predict and play. We had over 180 people during the 2019 World Series and playoffs."

The app and algorithm were good — and nVenue expanded into football. Then, the pandemic hit and sports halted completely. Pracht says they pivoted to a B2B model but wasn't seeing any real opportunities for the platform — until the 2021 Comcast NBCUniversal SportsTech Accelerator.

"In kind of a last-ditch effort, we applied to the NBC Comcast accelerator somewhere around August or September of 2020," Pracht says, explaining that she wasn't seeing a sustainable business so it was get into the program or close up shop. "And we got in. They just resonated with everything we said — we found our people."

The accelerator gave nVenue the jumpstart it needed, and as sports returned, the company found its momentum again. Now, the company is headquartered in Dallas with 14 employees all over and three — including Pracht — in Houston. The company has raised its $3.5 million seed round co-led by KB Partners and Corazon Capital and plans to raise a Series A next year.

After a few broadcasts last season, opportunity came knocking by way of Apple TV and Houston-based TV Graphics. The companies collaborated on a deal and, two weeks before the 2022 season started, nVenue got the greenlight to have onscreen analytics on Apple TV broadcasts.

"In under two weeks we structured the deal, convinced them it worked, pulled together every bit of testing we could — by then we only had one week of pre-season games to test — and we pulled it off," Pracht says.

The technology has tons of potential when it comes to sports betting, which is a growing business across the country. Pracht says nVenue isn't looking to compete with the providers on the scene, but instead work with them as an analytics tool.

"We broke down the market down to microbets or in-the-moment bets that are going to happen annually by 2025 — it's 156 billion microbets a year, which turns out to be 3 billion a week," Pracht says.

She adds that new technologies in the streaming world – like no-delay, latency streaming — is only going to make the sports betting world more lucrative, and nVenue will be right there to ride that wave.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston brain health co. secures $6.5M for rare disease study

neuro funding

Houston-based Goldenrod Therapeutics, part of Fannin Partners' portfolio, has announced the initial close of a $6.5 million series seed preferred stock round.

The round was led by Ataxia Ventures and an affiliate of Fannin, according to a news release.

Goldenrod Therapeutics plans to use the funding to support manufacturing, formulation optimization, IND-enabling studies and a Phase I study of its drug to treat brain inflammation, known as 11h.

The study will consider how 11h, which blocks the enzyme PDE4, could treat Friedreich’s ataxia (FA), a rare genetic disease that affects movement, speech and balance. To date, other PDE4 inhibitors have proven to regulate neuroinflammation and neuronal signaling, but have had adverse gastrointestinal side effects or have not reached enough of the central nervous system, according to Goldenrod.

The company says its 11h is expected to have "broad applicability" with limited emetric side effects.

“Our 11h program is a next-generation, orally bioavailable, brain-penetrant PDE4 inhibitor, where researchers overcame longstanding limitations associated with earlier PDE4 inhibitors," Dr. Dev Chatterjee, CEO of Goldenrod, said in the news release. "We believe this creates the potential for a best-in-class therapy for Friedreich’s Ataxia and a potential foundation for development across multiple neurodegenerative and neuroinflammatory disorders.”

11h was first developed at the University of Nebraska Medical Center (UNeMed). Houston-based Fannin Partners in-licensed the product 2020 and landed SBIR Phase I funding to support its initial development for opioid use disorder soon after.

Goldenrod has also received funding to study 11h's effectiveness for multiple sclerosis, methamphetamine addiction and cocaine addiction.

Goldenrod says it is developing 11h to target a variety of neurological and inflammatory conditions, including Alzheimer's disease, multiple sclerosis, ALS, substance use disorders, Batten disease, pain and traumatic brain injury.

27 Houston companies make Fortune 500 for 2026, led by energy giants

Houston HQs

Editor's note: This article has been updated to correct the number of companies based in the Dallas-Fort Worth area.

Houston is a giant among U.S. hubs for corporate headquarters.

The 2026 Fortune 500 lists 27 companies based in the Houston area, with many energy companies claiming top spots. Houston ties with Chicago for the second-most Fortune 500 headquarters, preceded only by New York City (53). Dallas-Fort Worth is home to 24 Fortune 500 headquarters.

Texas leads the nation for Fortune 500 headquarters (57), with California in the No. 2 spot and New York at No. 3.

“Texas is the undisputed headquarters of headquarters,” Gov. Greg Abbott said in a news release. “The world’s leading businesses invest with confidence in Texas because of our welcoming business climate, predictable regulatory environment, and skilled and growing workforce. People and businesses are choosing Texas because Texas works.”

The 2026 Fortune 500 ranks the largest U.S. corporations based on revenue in fiscal year 2025.

Here’s a rundown of the 27 Fortune 500 companies based in the Houston area.

  • No. 9 ExxonMobil
  • No. 21 Chevron
  • No. 29 Phillips 66
  • No.55 Sysco
  • No. 75 ConocoPhillips
  • No. 89 Enterprise Products Partners
  • No. 103 Plains GP Holdings
  • No. 133 Hewlett Packard Enterprise
  • No. 149 NRG Energy
  • No. 157 Quanta Services
  • No. 164 Baker Hughes
  • No. 173 Occidental Petroleum
  • No. 179 Waste Management
  • No. 201 EOG Resources
  • No. 204 Group 1 Automotive
  • No. 207 Halliburton
  • No. 223 Cheniere Energy
  • No. 236 Corebridge Financial
  • No. 262 Targa Resources
  • No. 266 Kinder Morgan
  • No. 388 Westlake
  • No. 435 CenterPoint Energy
  • No. 438 APA
  • No. 440 Comfort Systems USA
  • No. 455 NOV
  • No. 488 KBR
  • No. 496 Coterra Energy. Oklahoma City, Oklahoma-based Devon Energy and Houston-based Coterra Energy merged in early May, with the combined company retaining the Devon Energy name and the Houston headquarters.

The Greater Houston Partnership notes the Houston area soon will welcome its 28th Fortune 500 company. Expand Energy (formerly Chesapeake Energy), appearing at No. 362 on the 2026 list, says it’s moving its headquarters from Oklahoma City to Spring this year.

As the natural gas producer prepares to relocate to Texas, it’s hunting for a new leader. Nick Dell’Osso stepped down as president and CEO earlier this year. Board Chairman Michael Wichterich is interim president and CEO.

Dell’Osso became president and CEO of Oklahoma City-based Gulfport Energy effective May 28.

---

This article first appeared on EnergyCapitalHTX.com.

Elon Musk's SpaceX is about to make its debut on Wall Street

Money Moves

Elon Musk's rocket company SpaceX will make its debut on Wall Street Friday, June 12, and both institutional and retail investors are expected to gobble up the 555.6 million shares going up for sale at $135 apiece. Musk, already the world's richest man, could become its first trillionaire.

SpaceX is likely to become the biggest IPO ever, with proceeds of around $75 billion. SpaceX hopes to become the first company to send people to Mars. In fact, part of Musk’s future compensation depends on SpaceX eventually establishing a colony of at least 1 million people on the red planet.

Why SpaceX is going public now

In a video conference on Musk's social media platform X, he told JPMorgan CEO Jamie Dimon that people have suggested for the last 10 years that he take SpaceX public. He's doing it now because the company plans to put 100,000 next-generation Starlink satellites into orbit. Deploying AI data centers in space is a “massive new growth base and you need capital for that,” he said.

Going public provides access to the capital that SpaceX needs. But it also exposes it to more scrutiny from shareholders and more regulatory oversight. That includes filing quarterly financial reports, which critics say incentivizes short-term thinking over longer-term planning and creates unnecessary costs for a company. Securities regulators are currently soliciting public comment on a proposal to require public companies to file the financial reports only twice every year.

How the IPO impacts the company

Musk will hold the majority of a special class of shares, giving him control over decisions related to company strategy, finances and personnel. On the latter, because of his ownership of most of these Class B shares, the only person who can fire Musk as CEO is Musk.

The company credits Musk with being the “driving force” behind its growth, innovation and success. But what happens if Musk is no longer in the picture? SpaceX warns that the loss of Musk could disrupt its ability to execute its strategy as well as hurt its “reputation and relationships with customers, partners and other stakeholders.”

The company also warns that finding a replacement with the same skills and experience as Musk would be time-consuming, if not nearly impossible. As Wedbush Securities analyst Dan Ives wrote Wednesday, “At the end of the day Musk is SpaceX and SpaceX is Musk.”

What could make or break SpaceX

Currently in the test phase, the gigantic reusable Starship rocket is key to SpaceX realizing Musk's ambitions. Much of the commercial space business hinges on SpaceX developing Starship’s capability to be fully reusable and hearty enough for a quick turnaround between flights. If that doesn't happen, SpaceX warns that putting data centers and satellites in space will take longer and cost more money, meaning it risks customers bailing on the company.

Analysts say that by pioneering reusable rockets, SpaceX has established a clear lead on competitors such as Blue Origin, led by Amazon founder Jeff Bezos. The Starlink satellite business competes with, among others, AST SpaceMobile – which is relying on a SpaceX rocket to send its latest generation of satellites into orbit next week.

The prospectus filed last week says SpaceX’s biggest potential market is the sale of business-oriented artificial intelligence products designed to transform how people get work done. It’s an opportunity SpaceX predicts would be worth $22.7 trillion if it could somehow dominate rivals like Anthropic, OpenAI and Microsoft in a highly competitive industry. But the prospectus shows no clear path to profitability for the xAI business, which merged with SpaceX earlier this year.

Why Wall Street is paying attention

If the SpaceX IPO is as successful, the stock could quickly join the Nasdaq 100, a widely followed index that tracks the 100 largest non-financial companies in the composite. That's important because some popular funds, such as the $460 billion QQQ exchange-traded fund, mimic the index and will automatically buy whatever is listed in the index.

Nasdaq recently changed its rules to allow select companies to enter the Nasdaq 100 after just 15 trading days.

S&P Dow Jones Indices, on the other hand, is sticking to established and more traditional thresholds that will not allow SpaceX or other companies with gargantuan IPOs faster entry into its S&P 500 index. That means even high-profile companies will still need to wait for their stocks to trade a full 12 months before they can enter the index.

Companies want to be in the S&P 500 in particular because it's arguably the most important index on Wall Street, with trillions of dollars either mimicking it exactly or benchmarked against it. Vanguard's VOO fund that tracks the S&P 500 has roughly $950 billion invested in it, for example.